Follica lands $5.5M in first round

Boston-based Follica has landed $5.5 million in its first round of financing. Interwest Partners led the round and existing investors PureTech Ventures also contributed. Follica is developing a therapy for androgenetic alopecia and other hair follicle disorders. The company will use to funding to complete a clinical proof of concept study.

"There is a great need for novel therapies; androgenetic alopecia begins as early as the teenage years or twenties, and affects about half the men and women in the United States by the age of 50," noted Follica co-founder Vera Price.

- see this release for more

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.